accessibility menu, dialog, popup

UserName
Viewing profile as user:

Metal Aryls

Metal aryls are water-reactive, pyrophoric, organometallic coordination complexes containing aryl functional groups and metallic atoms. Available in various chemical compositions, quantities, purities, and reagent grades, they are often strong reducing agents.

Filtered Search Results

Products from some of our suppliers do not display in filtered search results. Please clear all filters to see these products.

Narrow Results

Narrow Results

category

brands

  • (2)

special interests

  • (2)
Search Within Results
Keyword Search:
1 – 2 of 2 results
1

Medchemexpress LLC 5-(hexahydropyrrolo[1,2-a]pyrazine-2-carbonyl)-4-chloro-2-fluoro-N-(2-fluorophenyl)benzenesulfonamide | 1235560-28-7 | MFCD29924737 | 99.3% | 457.48 g/mol | C20H20ClF2N3O3S | 10 MG
SDP

ABT-639 is a peripherally acting, selective T-type Ca2+ (CaV3.2) calcium channel blocker supplied as a research reagent. It has been investigated for analgesic and antihyperalgesic activity in preclinical and clinical studies and is provided as a high-purity solid for laboratory use.

  • Peripherally acting T-type Ca2+ channel blocker.
  • Selective for CaV3.2 T-type channels.
  • High purity suitable for research applications.
  • Supplied as a solid, convenient for formulation and dosing.
  • Intended for in vitro and in vivo research use; not for human use.

ENCOMPASS_PREFERRED
2

Medchemexpress LLC ABT-639 | 1235560-28-7 | 99.3% | 455.91 | 5 MG
SDP

ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. It is for research use only and not sold to patients.

  • Novel, peripherally acting, selective T-type Ca2+ channel blocker.
  • Blocks recombinant human T-type (Cav3.2) Ca2+ channels (IC50=2 μM).
  • Attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 μM).
  • Less active at other Ca2+ channels (e.g., Cav1.2, Cav2.2) (IC50>30 mM).
  • High oral bioavailability (%F=73), low protein binding (88.9%), low brain:plasma ratio (0.05:1) in rodents.
  • Produces dose-dependent antinociception in rat model of knee joint pain (ED50=2 mg/kg, p.o.).
  • Increases tactile allodynia thresholds in multiple models of neuropathic pain (10-100 mg/kg, p.o.).
  • Does not attenuate hyperalgesia in inflammatory pain models.
  • Does not significantly alter hemodynamic or psychomotor function at higher doses (e.g., 100-300 mg/kg).

ENCOMPASS_PREFERRED